These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12723456)

  • 1. Tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjects.
    Swan SK; Zhou H; Horowitz A; Alladina L; Hubert M; Appel-Dingemanse S; Osborne S; Lambrecht L; McLeod JF
    J Clin Pharmacol; 2003 Apr; 43(4):359-64. PubMed ID: 12723456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity.
    Appel-Dingemanse S
    Clin Pharmacokinet; 2002; 41(13):1021-42. PubMed ID: 12403641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects.
    Zhou H; Horowitz A; Ledford PC; Hubert M; Appel-Dingemanse S; Osborne S; McLeod JF
    J Clin Pharmacol; 2001 Oct; 41(10):1131-9. PubMed ID: 11583482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects-male and female, elderly and young.
    Appel-Dingemanse S; Horowitz A; Campestrini J; Osborne S; McLeod J
    Aliment Pharmacol Ther; 2001 Jul; 15(7):937-44. PubMed ID: 11421867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919).
    Appel-Dingemanse S; Hirschberg Y; Osborne S; Pommier F; McLeod J
    Eur J Clin Pharmacol; 2001 Mar; 56(12):889-91. PubMed ID: 11317476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.
    Appel-Dingemanse S; Lemarechal MO; Kumle A; Hubert M; Legangneux E
    Br J Clin Pharmacol; 1999 May; 47(5):483-91. PubMed ID: 10336571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tegaserod for the Treatment of Irritable Bowel Syndrome.
    Madia VN; Messore A; Saccoliti F; Tudino V; De Leo A; De Vita D; Bortolami M; Scipione L; Pindinello I; Costi R; Di Santo R
    Antiinflamm Antiallergy Agents Med Chem; 2020; 19(4):342-369. PubMed ID: 31518227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects.
    Degen L; Matzinger D; Merz M; Appel-Dingemanse S; Osborne S; Lüchinger S; Bertold R; Maecke H; Beglinger C
    Aliment Pharmacol Ther; 2001 Nov; 15(11):1745-51. PubMed ID: 11683688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial.
    Foxx-Orenstein AE; Camilleri M; Szarka LA; McKinzie S; Burton D; Thomforde G; Baxter K; Zinsmeister AR
    Neurogastroenterol Motil; 2007 Oct; 19(10):821-30. PubMed ID: 17539894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome.
    Hasler WL; Schoenfeld P
    Drug Saf; 2004; 27(9):619-31. PubMed ID: 15230644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review.
    Rivkin A
    Clin Ther; 2003 Jul; 25(7):1952-74. PubMed ID: 12946544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of tegaserod in the treatment of irritable bowel syndrome.
    Patel S; Berrada D; Lembo A
    Expert Opin Pharmacother; 2004 Nov; 5(11):2369-79. PubMed ID: 15500384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects.
    Zhou H; Khalilieh S; Svendsen K; Pommier F; Osborne S; Appel-Dingemanse S; Lasseter K; McLeod JF
    J Clin Pharmacol; 2001 Sep; 41(9):987-93. PubMed ID: 11549104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of tegaserod in irritable bowel syndrome management.
    Berardi RR
    J Am Pharm Assoc (2003); 2004; 44(1):41-51. PubMed ID: 14965152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tegaserod.
    Scott LJ; Perry CM
    Drugs; 1999 Sep; 58(3):491-6; discussion 497-8. PubMed ID: 10493276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and in vitro effects of tegaserod, a serotonin 5-hydroxytryptamine 4 (5-HT4) receptor agonist with prokinetic activity in horses.
    Delco ML; Nieto JE; Craigmill AL; Stanley SD; Snyder JR
    Vet Ther; 2007; 8(1):77-87. PubMed ID: 17447227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB; Wilhelm SM
    Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tegaserod-associated ischemic colitis.
    DiBaise JK
    Pharmacotherapy; 2005 Apr; 25(4):620-5. PubMed ID: 15977922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitro.
    Serebruany VL; El Mouelhi M; Pfannkuche HJ; Rose K; Marro M; Angiolillo DJ
    Am J Ther; 2010; 17(6):543-52. PubMed ID: 19797939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist.
    Appel S; Kumle A; Hubert M; Duvauchelle T
    J Clin Pharmacol; 1997 Mar; 37(3):229-37. PubMed ID: 9089425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.